A phase 2 study of Doxorubicin microneedle array - SkinJect (D-MNA) in Basal Cell Carcinoma patients in USA.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Mar 2025 New trial record
27 Feb 2025 According to Medicus Pharma media release, the company aims to get consent from the USFDA for fast-track the clinical development program. The discussion of product development and further alignment on the clinical pathway will be done in the Type C meeting with USFDA.
27 Feb 2025 According to Medicus Pharma media release, the Company is on track to complete an interim data analysis of SKNJCT-003 before the end of Q1 2025 and to submit its findings to the USFDA as part of a package seeking a Type C meeting with the FDA in Q2 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com